The Latest Endometriosis Industry Statistics Explained
The global endometriosis treatment market reached a value of nearly US$1.81 billion in 2020.
The statistic indicates that the global endometriosis treatment market was valued at approximately US$1.81 billion in 2020. Endometriosis is a chronic condition where the tissue similar to the lining of the uterus grows outside the uterus, leading to various symptoms like pelvic pain and infertility. The market value reflects the total spending on medications, surgeries, and other treatment options for managing endometriosis worldwide in that particular year. This figure highlights the significant economic impact of endometriosis on healthcare systems and the pharmaceutical industry, as well as the growing recognition of the importance of effective diagnosis and treatment of this debilitating condition.
The endometriosis market is projected to experience a compound annual growth rate (CAGR) of 4.7% from 2021 to 2027.
The statement indicates that the endometriosis market, which refers to the industry focused on developing and distributing treatments for endometriosis, is expected to grow at a steady pace over the period from 2021 to 2027. The compound annual growth rate (CAGR) of 4.7% implies that the market is forecasted to increase by an average of 4.7% per year during this time frame. This growth can be attributed to various factors such as increasing awareness of endometriosis, advancements in treatment options, changes in healthcare policies, and a growing patient population. Overall, the projection suggests a positive trend in the industry’s growth and potential opportunities for businesses operating within the endometriosis market.
The North American endometriosis market dominated the industry with over 37% market share in 2019.
The statistic indicates that the North American endometriosis market held a significant position within the industry in 2019, capturing more than one-third of the overall market share. This dominance suggests that North America was the leading region for endometriosis-related products and services, potentially due to factors such as higher prevalence rates of endometriosis, greater awareness and access to healthcare, advanced medical infrastructure, and higher levels of research and development investments in the region. The strong market share in North America highlights the region’s importance in the global endometriosis market and signifies its influence on industry trends, innovations, and outcomes related to endometriosis management and treatment.
Endometriosis affects an estimated 176 million women worldwide, which propels the growth of the industry.
The statistic that endometriosis affects an estimated 176 million women worldwide signifies the substantial impact of this condition on a global scale. Endometriosis is a chronic and often painful reproductive health disorder that occurs when tissue similar to the lining of the uterus grows outside of it, leading to various symptoms and complications. The sheer number of women affected highlights the widespread prevalence of endometriosis and the urgent need for research, treatment, and support services. This statistic also indicates the sizeable market potential for industries involved in developing innovative therapies, diagnostic tools, and healthcare solutions to address the needs of individuals living with endometriosis, further driving the growth and advancement of the healthcare sector.
More than 6.5 million women are affected by endometriosis in North America alone.
The statistic “More than 6.5 million women are affected by endometriosis in North America alone” highlights the significant prevalence and impact of this condition on women’s health in the region. Endometriosis is a chronic health condition in which tissue similar to the lining of the uterus grows outside of the uterus, causing symptoms such as chronic pelvic pain, painful periods, and infertility. The fact that over 6.5 million women are affected by endometriosis illustrates the widespread nature of this illness and the potential burden it places on individuals, healthcare systems, and society as a whole in terms of medical costs, decreased quality of life, and impact on productivity. This statistic underscores the importance of raising awareness, improving diagnosis and treatment, and providing support for women with endometriosis to address this significant public health issue.
The endometriosis treatment market in the Asia Pacific is estimated to grow at a CAGR of 5.1% between 2021-2027.
The statistic “The endometriosis treatment market in the Asia Pacific is estimated to grow at a compound annual growth rate (CAGR) of 5.1% between 2021-2027” indicates the projected annual growth rate of the market for treating endometriosis, a gynecological disorder affecting many women in the region. This CAGR of 5.1% suggests that the market is expected to expand steadily over the specified period, driven by factors such as increasing awareness, advancements in treatment options, and rising prevalence of endometriosis. The growth rate provides insight into the anticipated market expansion, helping stakeholders, healthcare professionals, and policymakers make informed decisions regarding investments, resource allocation, and healthcare planning to address the needs of patients with endometriosis in the Asia Pacific region.
The market for hormone therapy segment held over 52% share of the endometriosis market in 2019.
The statistic that the market for hormone therapy segment held over 52% share of the endometriosis market in 2019 indicates that more than half of the market for treating endometriosis was dominated by hormone therapy products or services during that year. This suggests that hormone therapy is a widely utilized and preferred treatment approach by healthcare providers and patients for managing endometriosis. The high market share of hormone therapy in the endometriosis market signifies its importance and effectiveness in addressing the symptoms and complications associated with this medical condition. Additionally, this statistic could also imply potential market opportunities for companies and manufacturers operating in the hormone therapy segment to further innovate and expand their offerings to meet the growing demand for endometriosis treatment options.
It is estimated that endometriosis is found in 24% to 50% of women who experience infertility.
This statistic indicates that a significant proportion of women who are diagnosed with infertility also have endometriosis, a condition in which tissue similar to the lining of the uterus grows outside of the uterus. The estimated range of 24% to 50% suggests variability in the prevalence of endometriosis among women experiencing infertility, highlighting the importance of considering this condition as a potential factor in fertility problems. Understanding this relationship is crucial for healthcare providers when evaluating and managing infertility issues in women, as diagnosing and treating endometriosis may improve overall reproductive outcomes.
The hospital pharmacies segment contributed over 48% of market revenue in 2020.
The statistic that the hospital pharmacies segment contributed over 48% of market revenue in 2020 indicates that a significant portion of the total revenue generated in the pharmaceutical market that year came from sales made through hospital pharmacies. This suggests that hospital pharmacies played a crucial role in driving the overall financial performance of the pharmaceutical sector in 2020. The high contribution percentage implies that hospital pharmacies were likely a key distribution channel for pharmaceutical products during that period, highlighting their importance in the industry’s revenue stream. Understanding the substantial impact of hospital pharmacies on market revenue can inform strategic decision-making processes for pharmaceutical companies and healthcare providers moving forward.
The global clinical trials market on endometriosis registered around 342 clinical trials as of May 2021.
The statistic stating that the global clinical trials market on endometriosis registered around 342 clinical trials as of May 2021 indicates a significant level of research activity and interest in studying treatments and interventions for endometriosis. Clinical trials are essential in advancing medical knowledge and improving healthcare outcomes for individuals with endometriosis. The number of trials suggests that there is ongoing effort in exploring potential therapies, diagnostic tools, and understanding the underlying mechanisms of the condition. This statistic highlights the dedication of the medical and scientific community to address the challenges faced by individuals living with endometriosis and potentially pave the way for new and improved treatments in the future.
Europe’s endometriosis market is expected to witness 5% CAGR by 2024.
This statistic indicates that the market for endometriosis treatment within Europe is anticipated to grow at a compound annual growth rate (CAGR) of 5% by the year 2024. This projected growth suggests a steady increase in the demand for endometriosis-related products and services in the European region over the specified time period. Factors driving this growth could include advancements in medical research, an increasing awareness of endometriosis, improvements in treatment options, and an expanding patient population. Investors, healthcare providers, and pharmaceutical companies operating in this market may use this statistic to make informed decisions regarding investments, expansion strategies, and product development efforts aimed at catering to the growing demand for endometriosis treatments in Europe.
Among endometriosis patients, more than 37% are likely to opt for conservative surgery procedures.
This statistic indicates that among individuals diagnosed with endometriosis, over 37% of them are inclined to choose conservative surgery as a treatment option. Conservative surgery in the context of endometriosis involves procedures aimed at preserving the reproductive organs while removing or managing the endometrial tissue. This statistic suggests that a significant portion of endometriosis patients prefer less invasive surgical interventions over more aggressive procedures, such as hysterectomy. Understanding the preferences of patients with endometriosis regarding their treatment options can help healthcare providers tailor their recommendations and optimize patient outcomes.
The direct healthcare cost of endometriosis was estimated to be $69.4 billion globally in 2019.
The statistic signifies that the total healthcare cost attributable to endometriosis, a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus, amounted to $69.4 billion on a global scale in 2019. This figure encapsulates expenses related to diagnosis, treatment, medications, hospitalizations, and other healthcare services directly associated with managing the condition. The magnitude of this cost underscores the substantial economic burden imposed by endometriosis on healthcare systems worldwide, emphasizing the need for continued research, improved access to care, and effective management strategies to alleviate the financial strain on individuals and healthcare systems grappling with this prevalent and debilitating condition.
Japan accounted for the largest share in the Asia Pacific endometriosis market with a value of $124.1 million in 2019.
This statistic indicates that in 2019, Japan had the highest market share in the Asia Pacific region specifically in the field of endometriosis, with a value of $124.1 million. This suggests that Japan’s economy and healthcare industry are major players in the market for endometriosis-related products and services in the region, outperforming other countries in terms of market size and expenditure on this particular health issue. By leading the market in endometriosis, Japan likely has a strong infrastructure for research, treatment, and awareness campaigns for this condition compared to other countries in the region.
About 48% of women with endometriosis are diagnosed with depression, driving the demand for more comprehensive endometriosis treatments.
The statistic indicates that approximately 48% of women with endometriosis also experience a diagnosis of depression, highlighting a significant overlap between the two conditions. This finding underscores the higher prevalence of depression among women with endometriosis compared to the general population. The co-occurrence of endometriosis and depression calls for a more holistic approach to treating these individuals, emphasizing the importance of addressing both physical and mental health aspects. As such, there is a growing demand for more comprehensive endometriosis treatments that not only focus on managing the physical symptoms of the condition but also incorporate mental health support to improve the overall well-being and quality of life of affected individuals.
The endometriosis market is highly competitive with multiple players accounting for a significant share, but AbbVie Inc. dominates the market.
The statistic suggests that the endometriosis market is crowded with a number of companies vying for market share, indicating a high level of competition within the industry. Despite this competitive landscape, AbbVie Inc. stands out as the leading player, holding a dominant position in the market. This dominance could be attributed to factors such as the company’s strong brand reputation, innovative products, effective marketing strategies, or significant investments in research and development. As a result, AbbVie Inc. is able to capture a substantial portion of the market share, potentially outperforming its competitors in the endometriosis market.
The endometriosis treatment market size for hospitals was valued around $967.8 million in 2020, showing significant market potential.
The statistic indicates that the endometriosis treatment market size specifically for hospitals reached a value of $967.8 million in 2020, reflecting the total amount of revenue generated from the sales of endometriosis-related treatments within hospital settings. This figure highlights a substantial market potential within the endometriosis treatment sector, as the sizeable revenue indicates a high demand for such treatments among patients seeking care in hospital settings. The significant market potential suggests that there is a lucrative opportunity for pharmaceutical companies, healthcare providers, and other stakeholders to invest in and further develop products and services tailored for the treatment of endometriosis in hospitals.
The oral contraceptives market segment is expected to grow at a CAGR of 6.3% during 2021-2026.
The statistic indicates that the oral contraceptives market segment is projected to experience a Compound Annual Growth Rate (CAGR) of 6.3% between the years 2021 and 2026. This suggests a steady and consistent annual growth rate over the specified time period. The CAGR reflects the compounded average rate at which the market is expected to expand, taking into consideration any fluctuations in growth rates year over year. With a CAGR of 6.3%, it indicates a positive outlook for the oral contraceptives market, indicating potential opportunities for market expansion and increased demand for oral contraceptives products over the next five years.
Around 50% of endometriosis is thought to be genetic, increasing the scope for personalized treatment plans.
The statistic that around 50% of endometriosis is thought to be genetic suggests that there is a significant hereditary component to the development of this condition. This finding implies that individuals with a family history of endometriosis may have an increased risk of developing the condition themselves. Understanding the genetic factors contributing to endometriosis opens up opportunities for personalized treatment plans that take into account a patient’s unique genetic profile. By identifying specific genetic markers associated with endometriosis, healthcare providers can tailor treatment strategies to target the underlying causes of the disease in each individual, potentially leading to more effective and personalized care.
References
0. – https://www.www.rcog.org.uk
1. – https://www.www.orbisresearch.com
2. – https://www.www.asrm.org
3. – https://www.www.gminsights.com
4. – https://www.www.alliedmarketresearch.com
5. – https://www.www.ncbi.nlm.nih.gov
6. – https://www.www.grandviewresearch.com
7. – https://www.clinicaltrials.gov
8. – https://www.www.marketdataforecast.com
9. – https://www.www.imarcgroup.com
10. – https://www.www.globenewswire.com
11. – https://www.pubmed.ncbi.nlm.nih.gov
